Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 11Other hematologic neoplasm 8Myeloid 8Thoracic 6Gastrointestinal 3Dermatologic 2Breast 2Tumor-Agnostic 1Sarcoma 1Plasma cell 1Other solid neoplasm 1Head & Neck 1Gynecologic 1Genitourinary 1Classical hematology 1

Conditions

Sarcoma, Synovial 1Sarcoma 1Liposarcoma, Myxoid 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Chondrosarcoma 1

Interventions

Radiotherapy 221Cyclophosphamide 211Doxorubicin 210Temozolomide 182Ifosfamide 121Filgrastim 111Imatinib Mesylate 104Etoposide 101Vincristine 92Gemcitabine 89Bevacizumab 83Magnetic Resonance Spectroscopy 81Irinotecan 79pembrolizumab 75Radiation 70Carboplatin 65Methotrexate 62pazopanib 61Nivolumab 58Cisplatin 58fludarabine phosphate 57Surgical Procedures, Operative 57Peripheral Blood Stem Cell Transplantation 57Specimen Handling 56Trabectedin 52Docetaxel 50Biopsy 50Busulfan 49Melphalan 46Paclitaxel 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
itacitinib × Sarcoma × Clear all
NCT03670069 2024-05-08

Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas

Fred Hutchinson Cancer Center

Phase 1 Terminated
27 enrolled
Sarcoma

Chondrosarcoma, Leiomyosarcoma, Sarcoma, Sarcoma, Synovial, Liposarcoma, Myxoid, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡